TIAPROFENIC ACID TROMETAMOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H12O3S.C4H11NO3
Molecular Weight	381.443
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TIAPROFENIC ACID TROMETAMOL

Structure Search

SMILES

NC(CO)(CO)CO.CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2

InChI

InChIKey=PDWBZKWQZFGXGU-UHFFFAOYSA-N

InChI=1S/C14H12O3S.C4H11NO3/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10;5-4(1-6,2-7)3-8/h2-9H,1H3,(H,16,17);6-8H,1-3,5H2

HIDE SMILES / InChI

Molecular Formula	C4H11NO3
Molecular Weight	121.135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H12O3S
Molecular Weight	260.308
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b

Tiaprofenic acid is a non-steroidal, anti-inflammatory, analgesic compound, which nonselectively inhibits cyclooxygenase protein. Tiaprofenic acid was approved in Europe for the symptomatic relief of arthritis, ankylosing spondylitis and other inflammatory-rheumatic disorders as well as the painful conditions after injury.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17652824	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Arthritis 87 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Palliative	Approved 8583	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Pain after injury 2 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Primary	Approved 8583	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Soft-tissue rheumatic conditions 2 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Palliative	Approved 8583	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.

C_max

Value	Dose	Co-administered	Analyte	Population
22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.55 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8864796/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
7.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
11.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
8.78 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
76.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
65.53 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
77.25 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
79.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
35.33 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8864796/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN
37.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
35.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
44.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
39.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8864796/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
2.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
2.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
2.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/301929/		TIAPROFENIC ACID serum	Homo sapiens
1.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3% OTHER https://www.medicines.org.uk/emc/product/2256#PHARMACOKINETIC_PROPS		TIAPROFENIC ACID plasma	Homo sapiens

Doses

Dose	Population	Adverse events
2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6333878/	healthy, ADOLESCENT Health Status: healthy Age Group: ADOLESCENT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6333878/	Sources: https://pubmed.ncbi.nlm.nih.gov/6333878/
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8612471/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8612471/	Sources: https://pubmed.ncbi.nlm.nih.gov/8612471/
300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/	Disc. AE: Chronic interstitial cystitis... AEs leading to discontinuation/dose reduction: Chronic interstitial cystitis (grade 3) Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/
300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	Disc. AE: Anorexia, Alkaline phosphatase increased... Other AEs: Lethargy... AEs leading to discontinuation/dose reduction: Anorexia Alkaline phosphatase increased ALT increased GGT increased Other AEs: Lethargy Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/

AEs

AE	Significance	Dose	Population
Chronic interstitial cystitis	grade 3 Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/
Lethargy		300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
ALT increased	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
Alkaline phosphatase increased	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
Anorexia	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
GGT increased	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/

PubMed

Title	Date	PubMed
Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans.	1993 Apr	8517101
Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis.	1993 Apr	8462374
Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.	1993 Jan	8423545
In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes.	2001 Jun	11484831
Effects of some nonsteroidal anti-inflammatory drugs on articular cartilage of rats in an experimental model of osteoarthritis.	2001 Mar	11426673
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis.	2001 Oct	11728078
Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes.	2002 Aug	12234061
The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety.	2002 Dec 27	12505292
[Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000].	2002 Jan-Feb	12090148
[Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)].	2002 Oct	12442124
The stereospecificity of flobufen metabolism in isolated guinea pig hepatocytes.	2003 Jun 5	12791169
Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.	2004 Aug 2	15226764
Effects of co-administered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery.	2005 Nov 7	16274480
[Patterns of non steroidal anti-inflammatory drug use in ambulatory care].	2006 Mar-Apr	16886702
Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.	2009	20015358
Contact dermatitis due to topical drugs.	2009 Oct	19834431
Hemorrhagic cystitis: A challenge to the urologist.	2010 Apr	20877590
Enhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis.	2010 Dec 1	21122103
The effect of terpenes on percutaneous absorption of tiaprofenic acid gel.	2010 Nov	21116781
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.	2015 Jan 5	25455453

Patents

Sample Use Guides

In Vivo Use Guide

The recommended daily dose range for adults is 600 mg tiaprofen acid per day divided into 2 doses.

Route of Administration: Oral

In Vitro Use Guide

Human osteoarthritic cartilage was treated with therapeutic doses of tiaprofenic acid (26 micrograms/ml; 2.6 micrograms/ml) in order to test the effect of the drug on the proteoglycan metabolism (catabolism and synthesis) and chondrocyte ultrastructure. The drug suppresed the proteoglycan metabolism by 38%.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:12:46 GMT 2025` Edited by `admin` on `Mon Mar 31 22:12:46 GMT 2025`
Record UNII	ZR3VFO4VD3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1,3-PROPANEDIOL, 2-AMINO-2-(HYDROXYMETHYL)-, 5-BENZOYL-.ALPHA.-METHYL-2-THIOPHENEACETATE (SALT)

Preferred Name

English

TIAPROFENIC ACID TROMETAMOL

Common Name

English

TROMETHAMINE 5-BENZOYL-.ALPHA.-METHYL-2-THIOPHENEACETATE

Common Name

English

2-THIOPHENEACETIC ACID, 5-BENZOYL-.ALPHA.-METHYL-, COMPD. WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)

Systematic Name

English

Code System Code Type Description

CAS

62715-04-2

Created by admin on Mon Mar 31 22:12:46 GMT 2025 , Edited by admin on Mon Mar 31 22:12:46 GMT 2025

PRIMARY

PUBCHEM

6454459

Created by admin on Mon Mar 31 22:12:46 GMT 2025 , Edited by admin on Mon Mar 31 22:12:46 GMT 2025

PRIMARY

FDA UNII

ZR3VFO4VD3

Created by admin on Mon Mar 31 22:12:46 GMT 2025 , Edited by admin on Mon Mar 31 22:12:46 GMT 2025

PRIMARY

EPA CompTox

DTXSID60978337

Created by admin on Mon Mar 31 22:12:46 GMT 2025 , Edited by admin on Mon Mar 31 22:12:46 GMT 2025

PRIMARY

Related Record Type Details


					1LS1T6R34C

TIAPROFENIC ACID

PARENT -> SALT/SOLVATE

Related Record Type Details


					1LS1T6R34C

TIAPROFENIC ACID

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

Description
Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b

C_max

T_1/2

F_unbound